PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosisZhe Wang|Journal for ImmunoTherapy of Cancer|2023Cited by 80
Development of Oral, Potent, and Selective CK1α Degraders for AML TherapyLu Huang, Wenchao Lu, Xiaozhong Peng et al.|JACS Au|2024Cited by 16